Publication | Open Access

Ph+ ALL patients in first complete remission have similar survival after reduced intensity and myeloablative allogeneic transplantation: impact of tyrosine kinase inhibitor and minimal residual disease

TransplantationOncologySimilar SurvivalImmunologyTransplantation MedicineHematologyGraft SurvivalGraft RejectionBlood TransplantationPh+ All PatientsMedicineCell TransplantationTyrosine Kinase Inhibitor